Supporter Spotlight

Ferring Pharmaceuticals

Ferring Pharmaceuticals, Inc. is a subsidiary of Ferring Pharmaceuticals, a privately owned, international company headquartered in Saint-Prex, Switzerland. Ferring identifies, develops and markets innovative products in therapeutic areas including women’s health, endocrinology, orthopedics, urology and infertility.

In its current work with Women in Government, Ferring is focusing on the growing issue of infertility. Infertility is a disease of the reproductive system that affects men and women equally and is recognized as such by the medical community, including the World Health Organization (WHO) and the American Congress of Obstetricians and Gynecologists (ACOG).

Infertility affects 1 in 8 couples in the United States, but with 21st century medical treatments, couples having trouble starting families have hope.  Indeed, modern medicine provides the means for promoting family building and helping those facing the disease of infertility to overcome it.

As of January, 2016, fifteen states offer some form of benefits for fertility coverage required by statute. Many of these statutes, however, require coverage for older, sub-optimal treatments.  The fact is, in the years since these states passed requirements for insurers to cover basic fertility treatments, more effective 21st century medical treatments have been advanced and developed. As a result of these new, advanced treatments, a much larger number of families are able to experience the joy of parenthood.

These same advances have sharply reduced the number of pregnancies resulting in multiple births (twins, triplets or more), which carry associated risk such as a higher incidence of mortality and premature delivery.  Reducing multiple births lowers these risks and significantly lowers costs. Indeed, according to a recent study, the national savings from fewer multiple births would be over $6 billion a year.

To learn more about Ferring, please visit​